Heart Test Laboratories Stock EBITDA
| HSCSW Stock | USD 0.03 0.00 0.00% |
Heart Test Laboratories fundamentals help investors to digest information that contributes to Heart Test's financial success or failures. It also enables traders to predict the movement of Heart Stock. The fundamental analysis module provides a way to measure Heart Test's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Heart Test stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -6.2 M | -6.5 M |
Heart | EBITDA |
Heart Test Laboratories Company EBITDA Analysis
Heart Test's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Heart Test EBITDA | (6.16 M) |
Most of Heart Test's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Heart Test Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Heart EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Heart Test is extremely important. It helps to project a fair market value of Heart Stock properly, considering its historical fundamentals such as EBITDA. Since Heart Test's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Heart Test's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Heart Test's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionHeart Ebitda
According to the company disclosure, Heart Test Laboratories reported earnings before interest,tax, depreciation and amortization of (6.16 Million). This is 100.7% lower than that of the Health Care Equipment & Supplies sector and 100.96% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.16% higher than that of the company.
Heart EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Heart Test's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Heart Test could also be used in its relative valuation, which is a method of valuing Heart Test by comparing valuation metrics of similar companies.Heart Test is currently under evaluation in ebitda category among its peers.
Heart Fundamentals
| Return On Equity | -2.69 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (379.07) % | ||||
| Revenue | 18.6 K | ||||
| EBITDA | (6.16 M) | ||||
| Net Income | (6.61 M) | ||||
| Cash And Equivalents | 723.48 K | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 1.04 M | ||||
| Current Ratio | 0.59 X | ||||
| Book Value Per Share | 6.55 X | ||||
| Cash Flow From Operations | (6.07 M) | ||||
| Earnings Per Share | (1.09) X | ||||
| Number Of Employees | 15 | ||||
| Beta | 3.29 | ||||
| Total Asset | 9.5 M | ||||
| Retained Earnings | (67.36 M) | ||||
| Working Capital | 5.6 M | ||||
| Net Asset | 9.5 M |
About Heart Test Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heart Test Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heart Test using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heart Test Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.